Angiotech announces results for the fourth quarter ended Decembe... (4927 14060 9993 24053 --------...)

HOME >> BIOLOGY >> TECHNOLOGY

Angiotech announces results for the fourth quarter ended December 31, 2007

Date:2/14/2008

4,927 14,060 9,993 24,053

-------------------------------------------------------------------------

Other income

(expenses):

Foreign exchange

gain (loss) 173 (173)i - (1,263) 1,263 i -

Investment and

other income 511 155 n 666 1,028 4 n 1,032

Interest expense

on long-term debt (12,774) 558 j (12,216) (11,891) 699 j (11,192)

Loss on redemption

of investments - - - 126 (126)l -

Loss on extinguish-

ment of debt - - - (9,297) 9,297 m -

-------------------------------------------------------------------------

(12,090) 540 (11,550) (21,297) 11,137 (10,160)

-------------------------------------------------------------------------

Income (loss) from

continuing

operations before

income taxes and

cumulative effect

of change in

accounting (19,103) 12,480 (6,623) (7,237) 21,130 13,893

Income tax expense

(recovery) (2,275) 3,149 k 874 (1,977) 3,880 k 1,903

-------------------------------------------------------------------------

Net (loss) income

from continuing

operations before

cumulative effect

of change in

accounting (16,828) 9,331 (7,497) (5,260) 17,250 11,990

-------------------------------------------------------------------------

Net loss from

discontinued

operations, net

of income taxes (4,448) 4,448 - (6,443) 6,443 -

-------------------------------------------------------------------------

Net (loss) income

for the period (21,276) 13,779 (7,497) (11,703) 23,693 11,990

-------------------------------------------------------------------------

Bas
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction

Post Your Comments:

Angiotech announces results for the fourth quarter ended Decembe...(4927 14060 9993 24053 --------...)